Followers | 134 |
Posts | 7040 |
Boards Moderated | 0 |
Alias Born | 02/09/2012 |
Thursday, April 15, 2021 8:26:42 AM
A Company can have:
1. the "Science" to prove out...and requires FDA approval in order to translate to Equity Value, (IPIX/Brilacidin)
2. They can have the "Management" to move it forward (Leo/DeGrado)...
3. but with no "Capital" ... nothing moves forward.
Without the Capital to move forward...the statement and/or suggestions that: "Follow the Money" is a MEASURE of Success or Failure at this stage of a drug development company is also an erroneous assertion based on a false assumption.
Without ALL three...the Science and product does not move forward. That was IPIX and Brilacidin...until 2020...
NOW...Leo has put the Third Leg on the stool...raised the capital for Brilacidin/Covid-19 AND other INDICATIONS...and has put BRILACIDIN in the bullseye of FDA.
SO THE PROCESS IS "FOLLOW THE SCIENCE"... "THEN FOLLOW THE MONEY"!
So right now... "Follow the Science"...
... which has been nothing but "STELLAR"...through RBL testing and giving it FDA recognition via Fast Track authorization and Investigational New Drug designation...leading to the CURRENT FDA CLINICAL TRIALS...
... listen to the PR and little birdies tweet "Alpha Viruses" and you will realize eyeballs are on Brilacidin for much bigger trophies than Covid-19 and its Variants...and
...wait for the Current clinical trial results...which dosing has been authorized to increase from 3 to 5 days of dosing to match Remdesivir protocol of 5 days and SoC in many U.S hospitals.
...THEN YOU CAN FOLLOW THE MONEY!!! (but of course, at a much greater price)
Upon demonstration in Phase II of success in disposing of ALL VARIANTS (since they are all Enveloped Viruses) and RBL testing showing high efficacy with ALPHA VIRUSES...
...IMO look for NOT "FOLLOW THE MONEY" ...but "CHASING THE MONEY" at over 20X, that is... $5.00 AS STARTERS and that's IMO a MINIMUN!
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:15:25 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/28/2023 01:00:08 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM